Apixaban
Brand: Eliquis (US/EU) / Apigat (IN) / Apixava (BD)
Anticoagulant
NOAC / DOAC (Xa inhibitor)
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 3 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 87 % |
| Volume of Distribution | 0.09 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Dual clearance (hepatic + renal); dose reduction in elderly, renal impairment, or low body weight. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Bleeding (especially GI), anemia, rare hypersensitivity
Contraindications:
Active major bleeding, severe hepatic impairment, mechanical heart valves
Precautions:
Dose adjustment in renal impairment and elderly; avoid abrupt discontinuation; reversal agent = Andexanet alfa